Bridging the Gap: Overcoming Scientific & Operational Barriers to MRD Integration in DLBCL
- Identifying the key knowledge gaps limiting ctDNA use in DLBCL, including variability in shedding, defining meaningful clearance thresholds, and linking molecular response to clinical decisions
- Confronting standardization challenges across assays and data pipelines to enable regulatory confidence and cross trial comparability
- Tackling logistical constraints and patient experience considerations to ensure ctDNA monitoring is feasible, timely, and truly beneficial in aggressive lymphoma settings